Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% of the general population. The histopathological and clinical abnormalities of NAFLD spectrum ranges from the accumulation of triglycerides in the liver to non-alcoholic steatohepatitis, that may progress to liver fibrosis and advanced cirrhosis.
The most serious clinical manifestations of NAFLD, i.e., NASH and cirrhosis, have very recently become the fastest growing indications for liver transplantation in western countries, heavily impacting on patient health, economic aspects and quality of life.
The association between NAFLD and diabetes is well established and there appears to exist an intricate interrelationship whereby the existence of one drive progression to the other. Diabetes seems to be the most important risk factor for NAFLD and the most important clinical predictor of the advanced forms of NAFLD; on the other hand, NAFLD is associated with a worse metabolic profile and a higher prevalence of microvascular and macro-vascular complications of diabetes, independently of other known risk factors. Despite the obvious health implications and the economic burden on the healthcare system due to the progressive nature of NAFLD and its higher prevalence (55-70%) in patients with diabetes, no pharmaceutical approaches have been approved to date, and the cornerstone in the prevention and treatment of NAFLD and its severe forms is represented by lifestyle modifications, including dietary interventions.
This research topic aims to give an updated overview on the prevention and treatment of NAFDL, both in type 1 and type 2 diabetes, ranging from the current dietary approaches, including quality/quantity modification of the diet as well as newest strategy such as intermitting fasting or ketogenic diet, to the novel pharmacological treatments, and considering also other interventions such as the effects of bariatric surgery in patients with obesity and coexisting NAFLD and type 2 diabetes.
Topic Editors welcome particularly original research on humans highlighting the latest progresses in research contributing to the treatment of NAFLD in patient with diabetes. Insightful systematicreviews and meta-analyses will also be appropriate and highly-considered.
We would like submissions which address the following sub-topic:
- Dietary interventions for the prevention and treatment of NAFLD in diabetes
- Glucose lowering drugs for the prevention and treatment of NAFLD in diabetes
- Novel drugs for the treatment of NAFLD and diabetes
- The effectiveness of pharmacological therapy in combination with lifestyle factors
- The effects of bariatric surgery on NAFLD in patients with obesity and type 2 diabetes
Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% of the general population. The histopathological and clinical abnormalities of NAFLD spectrum ranges from the accumulation of triglycerides in the liver to non-alcoholic steatohepatitis, that may progress to liver fibrosis and advanced cirrhosis.
The most serious clinical manifestations of NAFLD, i.e., NASH and cirrhosis, have very recently become the fastest growing indications for liver transplantation in western countries, heavily impacting on patient health, economic aspects and quality of life.
The association between NAFLD and diabetes is well established and there appears to exist an intricate interrelationship whereby the existence of one drive progression to the other. Diabetes seems to be the most important risk factor for NAFLD and the most important clinical predictor of the advanced forms of NAFLD; on the other hand, NAFLD is associated with a worse metabolic profile and a higher prevalence of microvascular and macro-vascular complications of diabetes, independently of other known risk factors. Despite the obvious health implications and the economic burden on the healthcare system due to the progressive nature of NAFLD and its higher prevalence (55-70%) in patients with diabetes, no pharmaceutical approaches have been approved to date, and the cornerstone in the prevention and treatment of NAFLD and its severe forms is represented by lifestyle modifications, including dietary interventions.
This research topic aims to give an updated overview on the prevention and treatment of NAFDL, both in type 1 and type 2 diabetes, ranging from the current dietary approaches, including quality/quantity modification of the diet as well as newest strategy such as intermitting fasting or ketogenic diet, to the novel pharmacological treatments, and considering also other interventions such as the effects of bariatric surgery in patients with obesity and coexisting NAFLD and type 2 diabetes.
Topic Editors welcome particularly original research on humans highlighting the latest progresses in research contributing to the treatment of NAFLD in patient with diabetes. Insightful systematicreviews and meta-analyses will also be appropriate and highly-considered.
We would like submissions which address the following sub-topic:
- Dietary interventions for the prevention and treatment of NAFLD in diabetes
- Glucose lowering drugs for the prevention and treatment of NAFLD in diabetes
- Novel drugs for the treatment of NAFLD and diabetes
- The effectiveness of pharmacological therapy in combination with lifestyle factors
- The effects of bariatric surgery on NAFLD in patients with obesity and type 2 diabetes
